Trial Profile
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Sertraline (Primary) ; Bupropion
- Indications Major depressive disorder
- Focus Biomarker; Therapeutic Use
- Acronyms EMBARC
- 15 Mar 2022 Key results published in the Biological Psychiatry
- 13 Apr 2021 Results from EMBARC and other studies, assessing the psychometric properties of the Pain Frequency, its impact on social functioning and quality of life and P-FIBS is a brief self-report measure of pain, published in the Journal of Clinical Psychiatry
- 02 Jan 2020 Results (n=221) published in the JAMA Psychiatry